Almost 3% of NSCLC patients exhibited the alterations in TFAP2C gene, of which 3.8% accounted for LUAD and 1.2% for LUSC subtypes (Figure 9E). The gene discussed is TFAP2C; the disease is non-small cell lung carcinoma.